Kairos Pharma, LTD. (KAPA) — research page
US · us-cm-kg/NYSE/KAPA · as of 2026-11-08
Identity and listing
The issuer is Kairos Pharma, LTD., listed on the NYSE under the ticker KAPA. The ISIN is not on the record. The LEI is not on the record. The security type is Corporate. The segment is not on the record. The sector is 2834 Pharmaceutical Preparations. The jurisdiction is United States, Delaware. The issuer is listed and not halted.
| field | value | source · read date |
|---|---|---|
| name | Kairos Pharma, LTD. | source · 2026-11-08 |
| exchange | NYSE | source · 2026-11-08 |
| ticker | KAPA | source · 2026-11-08 |
| ISIN | not on the record | |
| LEI | not on the record | |
| security type | Corporate | source · 2026-11-08 |
| segment | not on the record | |
| sector | 2834 Pharmaceutical Preparations | source · 2026-11-08 |
| jurisdiction | United States — Delaware | source · 2026-11-08 |
| status | listed, not halted | source · 2026-11-08 |
The disclosure read
The record holds 33 filings in the twelve months to 2026-11-08, across 27 filing days. The median gap between filing days is 9.0 days, against a median of 6.0 days for the NYSE and 6.0 days for the sector. The latest filing is dated 2026-11-05, which is 3 days before the record date. The latest filing is of type corporate news. The NYSE median filing count is 64.0 and the sector median is 63.0. The NYSE median latency is 4.0 days and the sector median latency is 4.0 days. The filings by type are 4 AGM/EGM, 11 corporate news, 7 directors' dealings, 3 prospectus, 4 regulatory filings and 4 results.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 33 | 9 | 3 |
| exchange median: NYSE (3256 issuers) | 64 | 6 | 4 |
| sector median: 2834 Pharmaceutical Preparations (526 issuers) | 63 | 6 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | corporate_news | 8-K | 8-K — 8-K (items 8.01,9.01) |
| 2026-11-03 | corporate_news | 8-K | 8-K — 8-K (items 1.01,8.01,9.01) |
| 2026-10-06 | corporate_news | 8-K | 8-K — 8-K (items 8.01,9.01) |
| 2026-09-14 | corporate_news | 8-K | 8-K — 8-K (items 7.01,9.01) |
| 2026-08-21 | corporate_news | 8-K | 8-K — 8-K (items 3.03,5.03,7.01,9.01) |
window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is Weinberg & Company P.A., located in Los Angeles, CA. The record holds no auditor changes.
Events and halts
The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.
Orderability
The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.
rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The record names 4 research houses on the issuer's investor-relations page: Maxim Group, HC Wainwright, EF Hutton and D. Boral Capital.
| research house | analyst | source · read date |
|---|---|---|
| Maxim Group | Jason McCarthy | issuer page · 2026-11-11 |
| HC Wainwright | Joe Pantginis | issuer page · 2026-11-11 |
| EF Hutton | Jason Kolbert | issuer page · 2026-11-11 |
| D. Boral Capital | Jason Kolbert | issuer page · 2026-11-11 |
Open research
The record holds 3 openly published research notes. Maxim Group published a note dated 2025-09-01, a note dated 2025-06-03 and a note dated 2025-03-27.
| date | publisher | note | kind |
|---|---|---|---|
| 2025-09-01 | Maxim Group | Positive Interim Phase 2 Data For ENV-105 in mCRPC Builds Compelling Profile and Extended PFS Benefit | issuer-sponsored |
| 2025-06-03 | Maxim Group | Kairos Pharma, Ltd. for ENV-105 in metastatic castration-resistant prostate cancer | issuer-sponsored |
| 2025-03-27 | Maxim Group | Targeting CD105 Could Extend SOC Prostate and Lung Cancer Treatments – Initiating Coverage with a Buy | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The issuer's sealed years are 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.
Sources
11 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)
- 10.2
- https://data.sec.gov/submissions/CIK0001962011.json (identity.jurisdiction)
- 10.3
- https://mcp.us-cm-kg.ai/events/NYSE/KAPA (the disclosure lines)
- 10.4
- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)
- 10.5
- https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm (the auditor)
- 10.6
- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.7
- https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx (coverage)
- 10.8
- https://kairospharma.com/wp-content/uploads/2025/09/Positive-Interim-Phase-2-Data-For-ENV-105-in-mCRPC-Builds-Co.pdf (open research)
- 10.9
- https://kairospharma.com/wp-content/uploads/2025/06/Maxim-Research-Report.pdf (open research)
- 10.10
- https://kairospharma.com/wp-content/uploads/2025/03/KAPA.Maxim_.032725.pdf (open research)
- 10.11
- https://mcp.us-cm-kg.ai/record/NYSE/KAPA (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"ticker":"KAPA","exchange":"NYSE"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:0250c1a06aa0e63b.